Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. . | This week on “The Top Line,” we explore the most anticipated drug launches of 2024.

Sales 189

Sales Pharma Marketing 189

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

World of DTC Marketing

MARCH 17, 2021

The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.

Pharma 186

Pharma Competition Prescription Sales 186

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Pharma 105

Pharma Networking Medicine Ethics 105

World of DTC Marketing

SEPTEMBER 9, 2021

If pharma is a business, they will find a way to develop, buy, or acquire new drugs. Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. New technologies are being developed that allow for virtual clinical trials and other cost-lowering development costs. healthcare spending will reach $6.2 healthcare.

Healthcare 222

Healthcare Healthcare Government Insurance 222

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical 98

Pharmaceutical Marketing Manufacturing Medicine 98

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

Prescription 52

Prescription Medicine Pharma 52

pharmaphorum

JUNE 27, 2022

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30

Biopharma 110

Biopharma Sales Prescription FDA 110

European Pharmaceutical Review

MARCH 14, 2024

billion by 2028, based on data from Evaluate Pharma. Prior to this new facility expansion, SK bioscience highlighted that in 2021, L HOUSE was the first domestic vaccine manufacturing facility to achieve EU-GMP certification from the European Medicines Agency (EMA).

Manufacturing 98

Manufacturing Marketing Medicine Pharma 98

European Pharmaceutical Review

MARCH 25, 2024

The facility is planned to be operational by 2028, Astellas said. Today marks a significant achievement for our company and reflects our continued commitment to expansion and innovation in the region,” declared Hideki Shima, Chief Manufacturing Officer, Astellas Pharma.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Engineering Government 98

Pharmaceutical Technology

SEPTEMBER 15, 2022

The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. AbbVie reported a 22.7%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

Medico Reach

JUNE 16, 2022

trillion by 2028. billion Pharma: $169.9 The industry was worth around 19.7% of the US GDP in 2020. The US national healthcare expenditure for 2020 was $4.1 trillion , which amounts to approximately $12,530 per person. This figure is supposed to reach $6.2 billion Medtech: $72.1 billion Provider: $197.8 billion Payer: $116.6

Healthcare 98

Healthcare Healthcare Distribution Healthcare Provider 98

European Pharmaceutical Review

OCTOBER 10, 2022

billion in 2028. The committee includes RNA experts Professor Robin Shattock of Imperial College London, Dr Lucy Foley CTO at eXmoor Pharma, Professor Dan Bracewell from UCL and Dr Jonathan Haigh from Fujifilm Diosynth Biotechnologies. Globally, the RNA-based therapeutics and vaccines market is predicted to be valued at $2.48

Training 98

Training Manufacturing Medicine Pharma 98

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. billion acquisition of Arena Pharma , bringing on board etrasimod in late-stage testing for ulcerative colitis, and made an $11.6 $PFE $GBT [link] pic.twitter.com/52AMCbvFHF.

Marketing 111

Marketing Sales Pharma FDA 111

European Pharmaceutical Review

SEPTEMBER 14, 2023

Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).

Competition 97

Competition Pharma Pharmaceutical 97

pharmaphorum

AUGUST 2, 2022

Roche isn’t the only pharma company looking at subcutaneous checkpoint inhibitors, but the phase 3 readout and a plan to submit the data for approval with regulators including the FDA and EMA puts it among the leaders in the category. Results from a trial in first-line NSCLC are due in early 2023.

Marketing 105

Marketing Competition Patients FDA 105

Clarivate

MAY 31, 2023

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52

Pharma Biopharma Medicine Healthcare 52

European Pharmaceutical Review

OCTOBER 12, 2023

AstraZeneca’s facilities in Macclesfield, the UK’s largest pharma manufacturing site, as well as Cambridge, Luton and Speke will all be supplied by energy from the new facility, which is currently being built. Astellas – sustainable innovation September also saw Astellas Pharma Inc. Kerry, Ireland.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

Patients 111

Patients Safety Sales Manufacturing 111

Pharmaceutical Technology

MAY 16, 2023

trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.

Marketing 52

Marketing Sales Pharma Leads 52

pharmaphorum

JANUARY 5, 2023

A new operating model for pharma shifted priorities and forced companies to rethink their organisational strategies. Everything from transitioning to virtual meetings with healthcare providers, to navigating the logistics of supply chain disruptions, has permanently altered pharma operations – many would say for the better.

Pharmaceutical 90

Pharmaceutical Recruitment Training Education 90

Pharmaceutical Technology

NOVEMBER 8, 2022

Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy Life Sciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year.

Food and Drug Administration 59

Food and Drug Administration Leads Pharma Food 59

European Pharmaceutical Review

MAY 2, 2023

Astellas Pharma has agreed to acquire ophthalmology biotech company Iveric Bio, Inc. The acquisition “seems to be the biggest” in the company ‘s history, Prashant Khadayate, Pharma Analyst at GlobalData observed. billion in 2028, according to GlobalData’s Pharma Intelligence Center. for approximately $5.9

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

European Pharmaceutical Review

AUGUST 15, 2022

According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. The pharma giant is not the only company facing challenges in the area, GAVI has also been warned of delays with Bharat Biotech’s rotavirus vaccine, Rotavac.

Manufacturing 98

Manufacturing Pharma Leads Pharmaceutical 98

pharmaphorum

DECEMBER 1, 2022

Billion by 2028. Billion by 2028. Exploring the implementation of complex in-vitro models for drug development. 3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.48 Masato Ohbuchi, Senior Researcher, Astellas.

Engineering 52

Engineering Management Media Pharmaceutical 52

pharmaphorum

AUGUST 2, 2022

As the technology has developed, the interest from larger pharma companies has continued to grow, resulting in a number of acquisitions and partnerships taking place to gain access to the technology. Looking to the future. It is for this reason that Merck is prepared to pay substantial sums to add ADC prospects and expertise to its business.

Marketing 98

Marketing Prospecting Sales Pharma 98

pharmaphorum

OCTOBER 10, 2022

The pharma group said earlier this year it is hoping for eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, and thrombosis as well as PAH, that will swell its sales from in the category to $10 billion around the end of the decade.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Marketing 59

PM360

SEPTEMBER 21, 2023

The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

JULY 12, 2022

The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028. The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

OCTOBER 10, 2022

As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.

Patients 98

Patients Pharma Media Training 98

pharmaphorum

NOVEMBER 2, 2022

” The deal also ties in with J&J’s plan to boost the margins it makes from its medical device and pharma divisions as it prepares to spin off its slower-growing consumer health business before the end of 2023 and chases down target revenues of $60 billion in 2025. Impella heart pump. Joaquin Duato.

Sales 52

Sales Medical Marketing Manufacturing 52

Pharmaceutical Technology

JANUARY 19, 2023

GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

OCTOBER 18, 2022

The pharma group has been steadily building a position in gene therapies, kickstarted by its $1 billion takeover of Prevail Therapeutics in 2020 that in turn led to the creation of the Lilly Institute for Genetic Medicine, also based in Boston, which is due to be fully operational in 2024.

Medicine 52

Medicine FDA Patients Pharma 52

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52